Antitumor activity
tumor, SD, CRB
DISEASE, TUMOR
A total of seven patients were response-evaluable: five from the 400 mg QD group and two from the 300 mg BID group. In the 400 mg QD group, two of five patients achieved a clinical response (ORR: 40.0%) and four of five patients achieved a clinical benefit (CBR: 80.0%). No clinical response (ORR and CRB) was reported in the 300 mg BID group. In the 400 mg QD group, two (40.0%) patients had confirmed PR, one of these patients achieved a duration of response of 40.4 weeks and the other patient achieved it for 16.9 weeks and remains in the study, with the duration of response continuing to be assessed. One of these 2 patients was pre‍-‍treated with fulvestrant. Two (40%) patients from the 400 mg QD group had SD, of which, one patient was pre-treated with fulvestrant. In the 300 mg BID group, both (100%) patients had progressive disease (Fig. Waterfall and swimmer plots. In the response-evaluable population, tumor shrinkage (relative change in tumor size from baseline to best overall response) was observed in four of five (80%) patients receiving amcenestrant 400 mg QD (and four of seven [57.1%] patients with a response to either dose), with one patient showing > 90% shrinkage of her target lesion (Fig. 